- ►karolinskauniversitetssjukhuset.se [PDF] SR Salpeter, E Greyber, GA Pasternak, EE … - Archives of Internal Medicine, 2003 - archinte.highwire.org Methods A comprehensive search was performed to identify all comparative trials
or observational cohort studies published between January 1, 1959, and March 31,
2002, that evaluated metformin therapy, alone or in combination with other ... Cited by 320 - Related articles - BL Direct - All 16 versions
- ►endojournals.org H Bays, L Mandarino, RA DeFronzo - Journal of Clinical Endocrinology & Metabolism, 2004 - Endocrine Soc Type 2 diabetes mellitus (T2DM) is characterized by insulin resistance in liver
and muscle and impaired insulin secretion. Considerable evidence also implicates
deranged adipocyte metabolism and altered fat topography in the ... Cited by 245 - Related articles - All 4 versions
SA Phillips, TP Ciaraldi, APS Kong, R … - Diabetes, 2003 - Am Diabetes Assoc The relationship between insulin action and control of the adipocyte-derived
factor adiponectin was studied in age- and weight-matched obese individuals with
type 2 diabetes failing sulfonylurea therapy. After initial metabolic ... Cited by 161 - Related articles - BL Direct - All 6 versions
KA Virtanen, K Hällsten, R Parkkola, T … - Diabetes, 2003 - Am Diabetes Assoc We evaluated the effects of rosiglitazone (4 mg bid) and metformin (1 g bid)
monotherapy for 26 weeks on adipose tissue insulin-stimulated glucose uptake in
patients (n = 41) with type 2 diabetes. Before and after the treatment, ... Cited by 111 - Related articles - BL Direct - All 4 versions
- ►endojournals.org I Pavo, G Jermendy, TT Varkonyi, Z Kerenyi, … - Journal of Clinical Endocrinology & Metabolism, 2003 - Endocrine Soc Pioglitazone, a thiazolidinedione, improves glycemic control primarily by
increasing peripheral insulin sensitivity in patients with type 2 diabetes,
whereas metformin, a biguanide, exerts its effect primarily by decreasing ... Cited by 104 - Related articles - BL Direct - All 5 versions
- Free from Publisher I Bogacka, H Xie, GA Bray, SR Smith - Diabetes Care, 2004 - Am Diabetes Assoc RESULTS—Pioglitazone treatment increased the expression of genes involved in
glycerol-3-phosphate synthesis. The mRNA expression of PEPCK-C and
glycerol-3-phosphate dehydrogenase (GPDH) increased (P < 0.01) in patients ... Cited by 103 - Related articles - BL Direct - All 8 versions
- ►diabetesjournals.org K Hällsten, KA Virtanen, F Lönnqvist, H … - Diabetes, 2002 - Am Diabetes Assoc Rosiglitazone, a thiazolidinedione, enhances peripheral insulin sensitivity in
patients with type 2 diabetes. Because the synergic action of insulin and
exercise has been shown to be decreased in insulin resistance, the aim of ... Cited by 97 - Related articles - BL Direct - All 6 versions
A Hammarstedt, V Rotter Sopasakis, S Gogg, … - Diabetologia, 2005 - Springer Abstract Aims/hypothesis: We examined whether short- term treatment with a
thiazolidinedione improves insulin sensitivity in non-obese but
insulin-resistant subjects and whether this is associated with an ... Cited by 46 - Related articles - All 3 versions
K Hallsten, KA Virtanen, F Lonnqvist, T … - Diabetic Medicine, 2004 - pt.wkhealth.com Aims: Peroxisome proliferator-activated receptor γ (PPARγ) activators have
recently been identified as regulators of cellular proliferation, inflammatory
responses and lipid and glucose metabolism. These agents prevent coronary ... Cited by 42 - Related articles - BL Direct - All 6 versions
